Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the neoantigen targeted therapies market grown in recent years?

The market size for neoantigen targeted therapies has experienced significant expansion recently. The growth is predicted to rise from $3.4 billion in 2024 to $4.72 billion in 2025, recording a compound annual growth rate (CAGR) of 38.7%. Factors contributing to this progress during the historic period include breakthroughs in genomic sequencing, progression of immunotherapy, insights into tumor immunology, successful clinical trials of checkpoint inhibitors, and advancements in molecular profiling.

How is the neoantigen targeted therapies market size expected to evolve during the forecast period?

The market size for neoantigen targeted therapies is predicted to experience significant expansion in the coming years, ballooning to a size of $16.01 billion in 2029, with a compound annual growth rate (CAGR) of 35.7%. This upward trend during the forecast period can be credited to progress in various areas, including bioinformatics, the broadening of precision medicine, the development of neoantigen vaccines, strategies combining therapies, and biomarker validation. The forecast period is also expected to see notable trends such as the management of neoantigen resistance, neoantigen-primed cell therapies, combinatorial therapies based on neoantigen, real-world data integration, and improved predictive models.

Get your neoantigen targeted therapies market report here!

https://www.thebusinessresearchcompany.com/report/neoantigen-targeted-therapies-global-market-report

Which key drivers are propelling the neoantigen targeted therapies market’s growth?

The growth of the neoantigen targeted therapies market is anticipated to be fueled by the escalating occurrence of cancer cases. The occurrence of cancer is defined as the sum of new cancer cases in a particular population over a certain period. Various types of cancer are often treated with neoantigen-targeted therapies in combination. As an example, the American Cancer Society (ACS), a voluntary health organization based in the United States, reported that in 2022, there were 1.9 million new cancer instances in the country, marking a substantial rise in comparison to previous years. Moreover, in 2022, around 609,360 deaths in the US were credited to cancer, highlighting the deep severity and effect of this illness on individuals and their families. Consequently, the escalating occurrence of cancer cases is contributing to the expansion of the neoantigen targeted therapies market.

What are the market segments in the neoantigen targeted therapies industry?

The neoantigen targeted therapies market covered in this report is segmented –

1) By Type: Monotherapy, Combination Therapy

2) By Immunotherapy Type: DNA Or RNA-Based Vaccines, Protein-Based Vaccines, Dendritic Cell Vaccines, TIL-Based Therapies

3) By Target Disease Indication: Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Bone Cancer, Gynecological Cancer

4) By Route Of Administration: Intradermal, Intravenous, Subcutaneous

5) By Application: Medical Research Institution, Hospital, And Clinic, Other Applications

Subsegments:

1) By Monotherapy: Individual Neoantigen-Targeted Treatments

2) By Combination Therapy: Neoantigen-Targeted Therapies Combined With Other Immunotherapies, Neoantigen-Targeted Therapies Combined With Chemotherapy, Neoantigen-Targeted Therapies Combined With Targeted Therapies

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11944&type=smp

Which leading companies are shaping the growth of the neoantigen targeted therapies market?

Major companies operating in the neoantigen targeted therapies market include F. Hoffmann-La Roche AG, Merck and Co. Inc., Bristol Myers Squibb Company, Eli Lilly and Company, Kite Pharma Inc., Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Bavarian Nordic Inc., Advaxis Inc., Immatics NV, Precision Biologics Inc., Iovance Biotherapeutics Inc., Agenus Inc., Achilles Therapeutics Plc, Medigene AG, Gritstone Bio Inc., SQZ Biotechnologies Company, Aduro BioTech Inc., Inovio Pharmaceuticals Inc., Gradalis Inc., EpiVax Inc., ISA Pharmaceuticals BV, Vaxon Biotech SA, Ziopharm Oncology, Genocea Biosciences Inc., Cellular Biomedicine Group Inc., Immunovaccine Inc.

What key trends are currently impacting the neoantigen targeted therapies market’s development?

Major firms in the neoantigen targeted therapies market are strategizing partnerships to customize cancer treatments and address the limitations of existing immunotherapy in managing solid tumors. Such strategic partnerships involve businesses utilizing each other’s capabilities and assets for reciprocal benefits and achievement. For example, in January 2023, the Germany-based biotech firm, BioNTech SE, entered into a partnership with the UK Government. This partnership’s goal is to offer personalized mRNA cancer immunotherapies to up to 10,000 patients by the year 2030. The collaboration encompasses numerous key sectors, such as cancer immunotherapy development, infectious disease vaccine research, and the establishment of a research and development centre in Cambridge. This joint effort will make use of the UK’s clinical trial infrastructure and health data resources to enhance patient enrolment and choose locations for BioNTech’s mRNA treatments’ trials. The company anticipates launching its inaugural clinical trials in the UK later this year, concentrating on cancer vaccines that may potentially be incorporated into routine treatment procedures if deemed effective.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11944

Which geographic areas are influencing the growth of the neoantigen targeted therapies market?

North America was the largest region in the neoantigen targeted therapies market in 2024. The regions covered in the neoantigen targeted therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Acute Myeloid Leukemia Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/acute-myeloid-leukemia-global-market-report

Cancer biologics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Point-of-Care Diagnostics Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/point-of-care-diagnostics-devices-and-equipment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: